Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL28544081 | 0.89 | ITGB3 (0.45) | ITGB3ITGA2BFAAHHDAC3HDAC4 | |
| SCHEMBL29528481 | 0.88 | FAAH (0.56) | FAAHEPHX2 | |
| SCHEMBL5550466 | 0.88 | FAAH (0.56) | FAAHEPHX2 | |
| SCHEMBL5550460 | 0.88 | FAAH (0.56) | FAAHEPHX2 | |
| SCHEMBL31722260 | 0.84 | SLC6A5 (0.54) | ITGB3ITGA2BFAAHHDAC3HDAC4 | |
| SCHEMBL21152612 | 0.84 | SLC6A5 (0.54) | ITGB3ITGA2BFAAHHDAC3HDAC4 | |
| SCHEMBL31722125 | 0.84 | SLC6A5 (0.54) | ITGB3ITGA2BFAAHHDAC3HDAC4 | |
| SCHEMBL29695436 | 0.84 | SLC6A5 (0.54) | ITGB3ITGA2BFAAHHDAC3HDAC4 | |
| SCHEMBL12914891 | 0.84 | SLC6A5 (0.54) | ITGB3ITGA2BFAAHHDAC3HDAC4 | |
| SCHEMBL12436306 | 0.83 | CHRNB2 (0.44) | ITGB3ITGA2BMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961424-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | Millennium Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134311-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2490720-A1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | Millennium Pharmaceuticals, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1575514-A2 | ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | Seattle Genetics, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050180972-A1 | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders | SEATTLE GENETICS, INC. | 2005-08-18 | — | — | US | disclosed |
| WO-2004032828-A2 | ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS | SEATTLE GENETICS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050180972-A1 | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders | CD209, FCGR1A, CD47 | ITGB3 403/4885ITGA2B 309/4885MMP2 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.